Modulation of Amphetamine-Induced Dopamine Release by Group II Metabotropic Glutamate Receptor Agonist LY354740 in Non-Human Primates Studied with Positron Emission Tomography
The DOI matches its Crossref record; 72 of the 72 references it cites were found in a registry or an index.
Abstract
Pharmacological evidence suggests that schizophrenia is associated with increased stimulation of dopamine (DA) D2 receptors. Recently, several groups have demonstrated that amphetamine-induced DA release is increased in schizophrenia, providing direct evidence for dysregulation of DA systems in this condition. In healthy volunteers, pretreatment with the noncompetitive N-methyl-D-aspartate (NMDA) antagonist ketamine increases amphetamine-induced DA release to levels similar to those observed in patients with schizophrenia. Therefore, the dysregulation of DA function observed in schizophrenia might be secondary to NMDA hypofunction. In this study, the regulation of this response by glutamate (GLU) transmission was further characterized by using a metabotropic glutamate (mGlu) receptor group II agonist to inhibit GLU transmission. The amphetamine- (0.5 mg/kg intravenously (i.v.)) induced decrease in [11C]raclopride equilibrium-specific binding (V3'') was measured under control conditions and following pretreatment with the mGlu2/3 receptor agonist LY354740 (20 mg/kg i.v.) in four baboons. Amphetamine reduced [11C]raclopride V3'' by 28+/-7% under control conditions. Following LY354740 pretreatment, amphetamine-induced reduction in [11C]raclopride V3'' was significantly enhanced (35+/-7%, p=0.002). The enhancement of the amphetamine-induced reduction in [11C]raclopride V3'' by LY354740 was not a simple additive effect, as LY354740 alone did not reduce [11C]raclopride V3''. In conclusion, the results of this study further document the involvement of GLU transmission in regulating the effect of amphetamine-induced DA release, and provide additional support to the hypothesis that the dysregulation of DA function revealed by the amphetamine challenge in schizophrenia might stem from a deficit in GLU transmission.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
A method for the solution of certain non-linear problems in least squares
Levenberg, K. (1944) · Quarterly of Applied Mathematics · doi:10.1090/qam/10666 · Cited by 12,359
Implications of Normal Brain Development for the Pathogenesis of Schizophrenia
Weinberger, D. R. (1987) · Archives of General Psychiatry · doi:10.1001/archpsyc.1987.01800190080012 · Cited by 3,724
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904 · cited 1×
“Laruelle, 2003 ) and decreased glutamate (GLU) transmission at N -methyl- D -aspartate (NMDA) receptors (see, for reviews,”
BackgroundDopamine in schizophrenia: a review and reconceptualization
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.11.1474 · Cited by 2,018
Rapid Automated Algorithm for Aligning and Reslicing PET Images
Woods, R. P., Cherry, S. R., & Mazziotta, J. C. (1992) · Journal of Computer Assisted Tomography · doi:10.1097/00004728-199207000-00024 · Cited by 1,912 · cited 1×
“PET images were coregistered to a volumetric T1-weighted magnetic resonance image (MRI) of the baboon's brain using an automated registration algorithm (”
MethodMoghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793 · cited 1×
“Ketamine blocks NMDA receptors, but also induces GLU release, resulting in the stimulation of other GLU receptors (”
BackgroundGlutamate receptor dysfunction and schizophrenia
Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685 · cited 1×
“While the fundamental pathophysiology of schizophrenia remains unknown, several lines of evidences suggest that this illness is associated with increased dopamine (DA) transmission at D2 receptors (see, for reviews, Carlsson, 1978; Seeman, 1987; Weinberger, 1987; Davis et al, 1991; Laruelle, 2003) and decreased glutam…”
BackgroundJentsch, J. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00060-8 · Cited by 1,314 · cited 1×
“While the fundamental pathophysiology of schizophrenia remains unknown, several lines of evidences suggest that this illness is associated with increased dopamine (DA) transmission at D2 receptors (see, for reviews, Carlsson, 1978; Seeman, 1987; Weinberger, 1987; Davis et al, 1991; Laruelle, 2003) and decreased glutam…”
BackgroundLaruelle, M., Abi-Dargham, A., van Dyck, C. H., Gil, R., D'Souza, C. D., Erdos, J., McCance, E., Rosenblatt, W., Fingado, C., Zoghbi, S. S., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.17.9235 · Cited by 1,291 · cited 1×
“Three studies have reported an increase in amphetamine-induced DA release in patients with schizophrenia (”
BackgroundSelf-citationBreier, A., Su, T.-P., Saunders, R., Carson, R. E., Kolachana, B. S., de Bartolomeis, A., Weinberger, D. R., Weisenfeld, N., Malhotra, A. K., Eckelman, W. C., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2569 · Cited by 1,154
Pharmacological agents acting at subtypes of metabotropic glutamate receptors
Schoepp, D. D., Jane, D. E., & Monn, J. A. (1999) · Neuropharmacology · doi:10.1016/s0028-3908(99)00092-1 · Cited by 1,060 · cited 1×
“LY354740 is a highly selective group II mGLU receptor agonist, with nanomolar affinity for the mGlu2 ( K i e75 nmolsl) and mGlu3 ( K i e93 nmolsl) receptors (”
BackgroundReversal of Phencyclidine Effects by a Group II Metabotropic Glutamate Receptor Agonist in Rats
Moghaddam, B., & Adams, B. W. (1998) · Science · doi:10.1126/science.281.5381.1349 · Cited by 1,006 · cited 1×
“Ketamine blocks NMDA receptors, but also induces GLU release, resulting in the stimulation of other GLU receptors (Moghaddam et al, 1997; Moghaddam and Adams, 1998).”
BackgroundMintun, M. A., Raichle, M. E., Kilbourn, M. R., Wooten, G. F., & Welch, M. J. (1984) · Annals of Neurology · doi:10.1002/ana.410150302 · Cited by 955 · cited 1×
“Brain activity was corrected for the contribution of plasma activity assuming a 5p blood volume (”
MethodImaging Synaptic Neurotransmission with in Vivo Binding Competition Techniques: A Critical Review
Laruelle, M. (2000) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200003000-00001 · Cited by 944
Self-citationCarr, D. B., & Sesack, S. R. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-10-03864.2000 · Cited by 880 · cited 1×
“The inhibitory pathway is provided by cortical glutamatergic efferents to midbrain GABAergic interneurons and striatomesencephalic GABA neurons (Carr and Sesack, 2000; Takahata and Moghaddam, 2000).”
BackgroundDopamine receptors and the dopamine hypothesis of schizophrenia
Seeman, P. (1987) · Synapse · doi:10.1002/syn.890010203 · Cited by 880 · cited 1×
“While the fundamental pathophysiology of schizophrenia remains unknown, several lines of evidences suggest that this illness is associated with increased dopamine (DA) transmission at D2 receptors (see, for reviews, Carlsson, 1978; Seeman, 1987; Weinberger, 1987; Davis et al, 1991; Laruelle, 2003) and decreased glutam…”
BackgroundNational electrical manufacturers association
(1926) · Journal of the A.I.E.E. · doi:10.1109/jaiee.1926.6537344 · Cited by 860
Increased Striatal Dopamine Transmission in Schizophrenia: Confirmation in a Second Cohort
Abi-Dargham, A., Gil, R., Krystal, J., Baldwin, R. M., Seibyl, J. P., Bowers, M., van Dyck, C. H., Charney, D. S., Innis, R. B., & Laruelle, M. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.6.761 · Cited by 803
Self-citationAntipsychotic Drugs, Neurotransmitters, and Schizophrenia
CARLSSON, A. (1978) · American Journal of Psychiatry · doi:10.1176/ajp.135.2.164 · Cited by 498
Brix, G., Zaers, J., Adam, L.-E., Bellemann, M. E., Ostertag, H. J., Trojan, H., Haberkorn, U., Doll, J., Oberdorfer, F., & Lorenz, W. J. (1997) · PubMed · Cited by 479
Abnormal Excitatory Neurotransmitter Metabolism in Schizophrenic Brains
Tsai, G. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950220039008 · Cited by 455
Molecular Diversity and Functions of Glutamate Receptors
Nakanishi, S., & Masu, M. (1994) · Annual Review of Biophysics and Biomolecular Structure · doi:10.1146/annurev.bb.23.060194.001535 · Cited by 446 · cited 1×
“To date, eight subtypes of mGlu receptors have been identified and classified into three subgroups (Nakanishi and Masu, 1994; Pin et al, 1999; Schoepp, 2002).”
BackgroundAbi-Dargham, A., Krystal, J. H., Anjilvel, S., Scanley, B. E., Zoghbi, S., Baldwin, R. M., Rajeevan, N., Ellis, S., Petrakis, I. L., Seibyl, J. P., et al. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.11.1550 · Cited by 405
Self-citationMonn, J. A., Valli, M. J., Massey, S. M., Wright, R. A., Salhoff, C. R., Johnson, B. G., Howe, T., Alt, C. A., Rhodes, G. A., Robey, R. L., et al. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm9606756 · Cited by 390 · cited 1×
“LY354740 Synthesis LY354740 was synthesized according to published methods (”
MethodMurase, S., Grenhoff, J., Chouvet, G., Gonon, F. G., & Svensson, T. H. (1993) · Neuroscience Letters · doi:10.1016/0304-3940(93)90641-w · Cited by 387
Kegeles, L. S., Abi-Dargham, A., Zea-Ponce, Y., Rodenhiser-Hill, J., Mann, J. J., Van Heertum, R. L., Cooper, T. B., Carlsson, A., & Laruelle, M. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00976-8 · Cited by 377
Self-citationKarreman, M., & Moghaddam, B. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.66020589.x · Cited by 357 · cited 1×
“The activating pathway is provided by a polysynaptic glutamatergic pathway onto the DA cells (see discussion and references in Gariano and Groves, 1988; Murase et al, 1993; Karreman and Moghaddam, 1996; Shim et al, 1996; see discussion and references in Carr and Sesack, 2000).”
BackgroundA simple synthesis of [11C]methyl triflate
Jewett, D. M. (1992) · International Journal of Radiation Applications and Instrumentation. Part A. Applied Radiation and Isotopes · doi:10.1016/0883-2889(92)90012-4 · Cited by 342 · cited 2×
“lMethyl triflate was produced by passing lmethyl iodide through a silver triflate furnace according to Jewett's procedure (”
MethodMolecular aspects of glutamate dysregulation: implications for schizophrenia and its treatment
Konradi, C., & Heckers, S. (2003) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(02)00328-5 · Cited by 336 · cited 1×
“While the fundamental pathophysiology of schizophrenia remains unknown, several lines of evidences suggest that this illness is associated with increased dopamine (DA) transmission at D2 receptors (see, for reviews, Carlsson, 1978; Seeman, 1987; Weinberger, 1987; Davis et al, 1991; Laruelle, 2003) and decreased glutam…”
BackgroundNeurotransmitter interactions in schizophrenia–therapeutic implications
Carlsson, A., Waters, N., & Carlsson, M. L. (1999) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00117-1 · Cited by 298
N‐Acetylaspartylglutamate Selectively Activates mGluR3 Receptors in Transfected Cells
Wroblewska, B., Wroblewski, J. T., Pshenichkin, S., Surin, A., Sullivan, S. E., & Neale, J. H. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69010174.x · Cited by 298 · cited 1×
“This observation is particularly relevant to the present study, as NAAG is an agonist at mGlu3 receptors (”
Monn, J. A., Valli, M. J., Massey, S. M., Hansen, M. M., Kress, T. J., Wepsiec, J. P., Harkness, A. R., Grutsch, Wright, R. A., Johnson, B. G., et al. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm980616n · Cited by 293 · cited 1×
“In the low micromolar range, agonist responses at the group III mGlu receptors mGlu6 and mGlu8 have been reported (”
BackgroundGariano, R. F., & Groves, P. M. (1988) · Brain Research · doi:10.1016/0006-8993(88)90606-3 · Cited by 286 · cited 1×
“The activating pathway is provided by a polysynaptic glutamatergic pathway onto the DA cells (see discussion and references in”
BackgroundHelton, D. R., Tizzano, J. P., Monn, J. A., Schoepp, D. D., & Kallman, M. J. (1998) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37253-2 · Cited by 279
Laruelle, M., Wallace, E., Seibyl, J. P., Baldwin, R. M., Zea-Ponce, Y., Zoghbi, S. S., Neumeyer, J. L., Charney, D. S., Hoffer, P. B., & Innis, R. B. (1994) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.1994.131 · Cited by 268
Self-citationMicrodialysis and SPECT measurements of amphetamine-induced dopamine release in nonhuman primates
Laruelle, M., Iyer, R. N., Al-Tikriti, M. S., Zea-Ponce, Y., Malison, R., Zoghbi, S. S., Baldwin, R. M., Kung, H. F., Charney, D. S., Hoffer, P. B., et al. (1997) · Synapse · doi:10.1002/(sici)1098-2396(199701)25:1<1::aid-syn1>3.0.co;2-h · Cited by 265 · cited 1×
“5 mgskg) reduced lraclopride V 3 ″ by 28±7p, a response consistent with previous observations (”
ResultSelf-citationSCHOEPP, D. D., JOHNSON, B. G., WRIGHT, R. A., SALHOFF, C. R., MAYNE, N. G., WU, S., COCKERHAM, S. L., PAUL BURNETT, J., BELEGAJE, R., BLEAKMAN, D., et al. (1997) · Neuropharmacology · doi:10.1016/s0028-3908(96)00160-8 · Cited by 225 · cited 1×
“LY354740 is a highly selective agonist at mGlu2s3 receptors (”
BackgroundVollenweider, F. X., Vontobel, P., Øye, I., Hell, D., & Leenders, K. L. (2000) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(99)00031-x · Cited by 223
Breier, A., Adler, C. M., Weisenfeld, N., Su, T.-P., Elman, I., Picken, L., Malhotra, A. K., & Pickar, D. (1998) · Synapse · doi:10.1002/(sici)1098-2396(199806)29:2<142::aid-syn5>3.0.co;2-7 · Cited by 201
Smith, P. D. (1998) · Neuropsychopharmacology · doi:10.1016/s0893-133x(97)00092-4 · Cited by 201
Gandelman, M. S., Baldwin, R. M., Zoghbi, S. S., Zea‐Ponce, Y., & Innis, R. B. (1994) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600830718 · Cited by 191
Quantitative Functional Brain Imaging with Positron Emission Tomography
(1998) · Elsevier eBooks · doi:10.1016/b978-0-12-161340-2.x5000-8 · Cited by 185
Battaglia, G., Monn, J. A., & Schoepp, D. D. (1997) · Neuroscience Letters · doi:10.1016/s0304-3940(97)00442-4 · Cited by 163
New perspectives for the development of selective metabotropic glutamate receptor ligands
Pin, J.-P., De Colle, C., Bessis, A.-S., & Acher, F. (1999) · European Journal of Pharmacology · doi:10.1016/s0014-2999(99)00258-7 · Cited by 158
Endogenous dopamine release after pharmacological challenges in Parkinson's disease
Piccini, P., Pavese, N., & Brooks, D. J. (2003) · Annals of Neurology · doi:10.1002/ana.10526 · Cited by 147 · cited 1×
“The effect of methamphetamine on lraclopride in vivo binding is also significantly blunted in patients with Parkinson's disease (”
BackgroundMiller, D. W., & Abercrombie, E. D. (1996) · Brain Research Bulletin · doi:10.1016/0361-9230(95)02144-2 · Cited by 146 · cited 1×
“In contrast, systemic administration of noncompetitive NMDA antagonists increased amphetamine-induced DA release measured with microdialysis in rodents (Miller and Abercrombie, 1996) and with SPECT in humans (Kegeles et al, 2000).”
BackgroundTsukada, H., Nishiyama, S., Kakiuchi, T., Ohba, H., Sato, K., Harada, N., & Nakanishi, S. (1999) · Brain Research · doi:10.1016/s0006-8993(99)02018-1 · Cited by 124
Wróblewska, B., Santi, M. R., & Neale, J. H. (1998) · Glia · doi:10.1002/(sici)1098-1136(199810)24:2<172::aid-glia2>3.0.co;2-6 · Cited by 118
Deisz, R. A., Billard, J.-M., & Zieglg�nsberger, W. (1997) · Synapse · doi:10.1002/(sici)1098-2396(199701)25:1<62::aid-syn8>3.0.co;2-d · Cited by 112
Self-citationTarget‐Specific Glutamatergic Regulation of Dopamine Neurons in the Ventral Tegmental Area
Takahata, R., & Moghaddam, B. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0751775.x · Cited by 101 · cited 1×
“The inhibitory pathway is provided by cortical glutamatergic efferents to midbrain GABAergic interneurons and striatomesencephalic GABA neurons (Carr and Sesack, 2000; Takahata and Moghaddam, 2000).”
BackgroundTsukada, H., Nishiyama, S., Kakiuchi, T., Ohba, H., Sato, K., & Harada, N. (1999) · Brain Research · doi:10.1016/s0006-8993(99)01834-x · Cited by 100
Tsukada, H., Harada, N., Nishiyama, S., Ohba, H., & Kakiuchi, T. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-18-07067.2000 · Cited by 99
NMDA antagonist effects on striatal dopamine release: Positron emission tomography studies in humans
Kegeles, L. S., Martinez, D., Kochan, L. D., Hwang, D., Huang, Y., Mawlawi, O., Suckow, R. F., Van Heertum, R. L., & Laruelle, M. (2002) · Synapse · doi:10.1002/syn.10010 · Cited by 94
Self-citationTsukada, H., Miyasato, K., Kakiuchi, T., Nishiyama, S., Harada, N., & Domino, E. F. (2002) · Synapse · doi:10.1002/syn.10102 · Cited by 91
Lindenau, J., Noack, H., Asayama, K., & Wolf, G. (1998) · Glia · doi:10.1002/(sici)1098-1136(199810)24:2<252::aid-glia10>3.0.co;2-z · Cited by 82
East, S. J., Hill, M. P., & Brotchie, J. M. (1995) · European Journal of Pharmacology · doi:10.1016/0014-2999(95)00119-6 · Cited by 80 · cited 1×
“Activation of mGlu2s3 receptors reduces GLU release (”
BackgroundSaba, W., Cavorsin, M. L., Ginovart, N., Zimmer, L., Gualda, V., Bonnefoi, F., & Leviel, V. (2003) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-002-0904-4 · Cited by 77 · cited 1×
“Duvaldestin, 1981 ), anesthesia induction by ketamine does not affect lraclopride binding (”
BackgroundKetamine does not decrease striatal dopamine D 2 receptor binding in man
Aalto, S., Hirvonen, J., Kajander, J., Scheinin, H., Någren, K., Vilkman, H., Gustafsson, L. L., Syvälahti, E. K. G., & Hietala, J. A. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1236-6 · Cited by 75
Di Iorio, P., Battaglia, G., Ciccarelli, R., Ballerini, P., Giuliani, P., Poli, A., Nicoletti, F., & Caciagli, F. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.67010302.x · Cited by 66 · cited 1×
“Battaglia et al , 1997 ), whereas mGlu2s3 receptor antagonists amplify the elicited release of GLU (”
BackgroundNMDA antagonist effects on striatal dopamine release: Microdialysis studies in awake monkeys
Adams, B. W., Bradberry, C. W., & Moghaddam, B. (2002) · Synapse · doi:10.1002/syn.1114 · Cited by 58 · cited 1×
“Three studies have reported an increase in amphetamine-induced DA release in patients with schizophrenia (”
BackgroundDopamine Transmission in the Schizophrenic Brain
Laruelle, M. (2003) · Schizophrenia · doi:10.1002/9780470987353.ch20 · Cited by 53 · cited 1×
“While the fundamental pathophysiology of schizophrenia remains unknown, several lines of evidences suggest that this illness is associated with increased dopamine (DA) transmission at D2 receptors (see, for reviews, Carlsson, 1978; Seeman, 1987; Weinberger, 1987; Davis et al, 1991; Laruelle, 2003) and decreased glutam…”
BackgroundSelf-citationVillemagne, V. L., Wong, D. F., Yokoi, F., Stephane, M., Rice, K. C., Matecka, D., Clough, D. J., Dannals, R. F., & Rothman, R. B. (1999) · Synapse · doi:10.1002/(sici)1098-2396(19990915)33:4<268::aid-syn3>3.0.co;2-w · Cited by 52
Denman, A. M. (2004) · The British Journal of Psychiatry · doi:10.1192/bjp.184.3.280 · Cited by 52
Reimer, M. L. J., Mamer, O. A., Zavitsanos, A. P., Siddiqui, A. W., & Dadgar, D. (1993) · Biological Mass Spectrometry · doi:10.1002/bms.1200220404 · Cited by 48 · cited 1×
“Amphetamine was quantified as its N -heptafluorobutyryl derivative via gas chromatographysmass spectroscopy utilizing a capillary column with mass spectrometer with simultaneous ion monitoring in the negative chemical ionization mode and reactant gas methanesammonia (95 : 5) (”
MethodMao, L., & Wang, J. Q. (2000) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(00)00307-5 · Cited by 46
Mao, L., Lau, Y., & Wang, J. Q. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00633-6 · Cited by 37 · cited 1×
“Yet, activation of group III mGlu receptors inhibits amphetamine-stimulated DA release (”
BackgroundMetabotropic glutamate receptors
Schoepp, D. D. (2002) · Pharmacology Biochemistry and Behavior · doi:10.1016/s0091-3057(02)00824-9 · Cited by 29
Bindel, T. H. (1989) · Journal of Chemical Education · doi:10.1021/ed066p847 · Cited by 25
Effects of Lesions in the Medial Prefrontal Cortex on the Activity of Midbrain Dopamine Neurons
Seong, S. (1996) · Neuropsychopharmacology · doi:10.1016/s0893-133x(96)00052-8 · Cited by 24
Pharmacokinetics in Intravenous Anaesthetic Practice
Duvaldestin, P. (1981) · Clinical Pharmacokinetics · doi:10.2165/00003088-198106010-00003 · Cited by 20 · cited 1×
“Owing to the short half-life of ketamine (Duvaldestin, 1981), anesthesia induction by ketamine does not affect [(11)C]raclopride binding (Hassoun et al, 2003).”
Backgroundvan Berckel, B. N. M. (2003) · Current Neuropharmacology · doi:10.2174/1570159033477026 · Cited by 9
Laruelle, M. A., Abi‐Dargham, A., & Innis, R. B. (1998) · Elsevier eBooks · doi:10.1016/b978-012161340-2/50070-6 · Cited by 4
Self-citation
Research works printed but not linked: 1
- Kim SE, Shin I, Oh SJ, Kim SH, Choe YS, Choi Y et al (1998). Nicotine-induced dopamine release evaluated with in vivo3H raclopride binding studies: comparison with in vivo dialysis data. J Nucl Med 39: 54P.
Cited by
Faraone, S. V. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.02.001 · Cited by 631
“…al., 2007; Saelens et al., 1980; Schiffer et al., 2006; Seneca et al., 2006; Sun et al., 2003; Tomic et al., 1997; Tomic and Joksimovic, 2000; van Berckel et al., 2006) and NE receptors (Finnema et al., 2015; Landau et al., 2012), which is an indirect indicator of increased competition for…”
Javitt, D. C. (2007) · International Review of Neurobiology · doi:10.1016/s0074-7742(06)78003-5 · Cited by 560
From drugs to deprivation: A Bayesian framework for understanding models of psychosis
Corlett, P. R., Frith, C. D., & Fletcher, P. C. (2009) · Psychopharmacology · doi:10.1007/s00213-009-1561-0 · Cited by 367
“This suggestion was confirmed in primates administered with amphetamine: PET showed that amphetamine-induced dopamine release was blocked by a metabotropic glutamate receptor agonist (van Berckel et al. 2006).”
BackgroundThe acute effects of NMDA antagonism: From the rodent to the human brain
Gunduz-Bruce, H. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2008.07.006 · Cited by 182
Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists
Krystal, J. H., Mathew, S. J., DʼSouza, D. C., Garakani, A., Gunduz-Bruce, H., & Charney, D. S. (2010) · CNS Drugs · doi:10.2165/11533230-000000000-00000 · Cited by 180
Metadata
- Authors
- van Berckel, B. N. M., Kegeles, L. S., Waterhouse, R., Guo, N., Hwang, D.-R., Huang, Y., Narendran, R., Van Heertum, R., & Laruelle, M.
- Affiliations
- Columbia University (US)
- Venue
- Neuropsychopharmacology
- Published
- 2005-09-21
- Volume
- 31
- Issue
- 5
- Pages
- 967-977
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2049064370
- Cited by
- 43
- References
- 70
- Citations by year
- 2020: 1 · 2019: 1 · 2018: 1 · 2017: 1 · 2015: 1 · 2014: 2 · 2013: 3 · 2012: 2
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- National Alliance for Research on Schizophrenia and Depression
- National Institutes of Health (5k08mh001594-05, 5p30mh059342-02)
- National Institute of Mental Health (K02 MH01603, K02MH001603, MH59342-01, 1 K08 MH01594)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- amphetamine-induced dopamine release, group II metabotropic glutamate receptors, LY354740, glutamatergic neurotransmission, schizophrenia, ketamine, [11C]raclopride, D2 receptor binding, baboons, dopamine dysregulation
- MeSH terms
- Amphetamine, Animals, Bridged Bicyclo Compounds, Brain, Dopamine, Female, Male, Radioligand Assay, Schizophrenia, Dopamine Agents, Receptors, N-Methyl-D-Aspartate, Receptors, Dopamine D2, Receptors, Metabotropic Glutamate, Dopamine Antagonists, Excitatory Amino Acid Agonists, Raclopride, Papio anubis, Positron-Emission Tomography
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.